April 5, 2017
Radiopharmaceuticals market could double up in 4 years
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
April 4, 2017
FDA will look into Janssen’s sNDA for ibrutinib
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
April 4, 2017
Cannabics Pharmaceuticals gets final report of its research on antitumor properties of cannabinoids in Israel
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
April 4, 2017
Creso Pharma welcomes new COO
Creso Pharma has appointed pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
April 4, 2017
Galapagos in three new Phase 2 studies with filgotinib
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.
April 4, 2017
Verona Pharma doses first patients in UK testing its cystic fibrosis candidate
Verona Pharma has dosed the first patient in a phase 2a test of its candidate RPL554 for cystic fibrosis, the most common fatal inherited disease in the United States and Europe.
April 4, 2017
FDA OK’s Teva’s Huntington’s disease drug
U.S. Food and Drug Administration (FDA) has approved Teva’s Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease (HD).
April 4, 2017
Shield Therapeutics welcomes new financial boss to the Group
Shield Therapeutics will welcome new Chief Financial Officer to the Group, who will be a Board member, in the beginning of the month of May 2017.
April 3, 2017
FDA grants Kitov waiver for New Drug Application filing fee
Kitov Pharmaceuticals Holdings Ltd, a NASDAQ and TASE listed innovative biopharmaceutical company, said Monday that that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application filing fee for Kitov’s patented combination of …
April 3, 2017
Incyte, Bristol-Myers Squibb move epacadostat plus Opdivo combination into pivotal studies
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.